Clinical Trial: Clinical Characteristics of Patients With Anti-Collapsin Response Mediator Protein 2 Antibodies in Encephalitis or Encephalomyelitis

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07036042) titled 'Clinical Characteristics of Patients With Anti-Collapsin Response Mediator Protein 2 Antibodies in Encephalitis or Encephalomyelitis' on June 17.

Brief Summary: Autoimmune encephalitis (AE) is an important autoimmune neurological disease, and its clinical manifestations, treatment and prognosis are closely related to the type of pathogenic antibodies. However, due to the limited antibody spectrum and the unclear pathogenic mechanism, the disease is difficult to diagnose and treat, and the morbidity and mortality rates are high. In a previous study, we found that anti-CRMP2 antibodies were AE-specific autoantibodies, adding a new mem...